add site
services
publishers
database
health videos
toolbar
stats
live show
health store
more stuff
JOIN/LOGIN
| advertise add site services publishers database health videos
| | about toolbar stats live show health store more stuff JOIN/LOGIN |
| Health World US Business Political Technology Entertainment Sports Popular |
REG-Lilly (Eli) & Co: STATEMENT ON FDA'S BYETTA (EXENATIDE) INJECTION UPDATEReuters - Nov 2, 2009 Data indicate that weight loss (even a modest amount) supports patients in their efforts to achieve and sustain glycemic control., About BYETTA® (exenatide) ... Byetta Label RevisedZacks.com - Nov 27, 2009 Amylin Pharmaceuticals (NASDAQ: AMLN): Upgraded To Overweight At Barclays ...istockAnalyst.com (press release) - Nov 24, 2009 With focus on exenatide LAR as a primary value driver, however, uncertainty has persisted regarding approvability in the context of FDA concerns expressed ... Biggest Small Cap Stock Gainers are AMLN, DSW, IWA TransWorldNews (press release) Good News for Alkermes' PipelineZacks.com - Nov 18, 2009 We remind investors that a key action date for Alkermes is coming up in 2010 when the FDA decides on the company's type II diabetes candidate, exenatide ... Up-Trend Outlook: ALKS, CHBT, BPHX Small Cap Network New treatments and technologies ease burden on diabetes patientsDallas Morning News - - Nov 3, 2009 The second, exenatide, a synthetic version of the gila monster saliva molecule, stimulates the pancreas to make more insulin. One side effect of exenatide, ... US Patent Allowed for NOD TechPR Newswire (press release) - Nov 24, 2009 NOD technology is a platform technology that can be applied to many macromolecular drugs such as insulin, interferon, growth hormone, exenatide, ... FDA approved expanded indication for exenatideEndocrine Today - Nov 3, 2009 The FDA has approved exenatide injection for use as monotherapy along with diet and exercise to improve glycemic control in adults with type 2 diabetes. ... Amylin Pharmaceuticals Inc. Reports Operating Results (10-Q)GuruFocus.com - Nov 5, 2009 (1) Research and development expenses for our diabetes programs consist primarily of costs associated with BYETTA and exenatide once weekly which are shared ... US HOT STOCKS: J. Crew, Coldwater Active In Late TradingWall Street Journal - Nov 24, 2009 New treatments options give increased freedom to diabetes patientsExaminer.com - Nov 6, 2009 The second, exenatide, a synthetic version of the gila monster saliva molecule, stimulates the pancreas to make more insulin. One side effect of exenatide, ... | How to call the show... 1) Make sure the show is live (see graphic above). 2) Dial 724-444-7444. 3) Enter Call ID# 27566 when prompted. 4) Follow the phone prompts to join the call. Would you like to be a special guest on the show? Send us an email which includes your contact information and the topic(s) that you would like to discuss. Listen to past shows featuring special guests...  Bernard von NotHaus (Liberty Dollar)Aubrey de Grey, PhDDr. Amanuel Sima, MDDr. Bard Levey, DDSNeal AdamsRobin Scovill (director)Richard Diaz (author)Dr. Kaayla T. Daniel, CCNChana de Wolf, (cryonics researcher)Dr. Mary Ruwart (author & scientist)Richard Diaz (author)Dr. Jason Helliwell, OB/GYN |
| ↑ top of page ↑ | about thumbshots |
